Latest News
Category: ASX
Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision...
Read more
Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise...
Read more
Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August...
Read more
Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds),...
Read more
Telix today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2...
Read more
Telix today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments for diagnostic radiopharmaceuticals...
Read more
Telix today announces that it has elected to withdraw its proposed initial public offering (IPO) in the United...
Read more
Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET...
Read more
Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic...
Read more
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”)...
Read more